PFO
ARCT icon

Pathstone Family Office’s Arcturus Therapeutics ARCT Stock Holding History

Pathstone Family Office’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-250
Closed -$11K – 699
2020
Q4 		$11K Buy
+250
New +$16.9K ﹤0.01% 857

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Family Office's ARCT Position: Q1 2021 in Review

Pathstone Family Office sold out of Arcturus Therapeutics (ARCT) in Q1 2021, closing a stake of 250 shares — an estimated $11K sold.

Pathstone Family Office first reported a position in ARCT in Q4 2020 and held it in 1 quarter. The position peaked at $11K in Q4 2020. 162 funds tracked by Wall St. Rank hold ARCT as of Q1 2021.

  • Pathstone Family Office reported no remaining Arcturus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Pathstone Family Office sold 250 Arcturus Therapeutics shares in Q1 2021, an estimated $11K.
  • Pathstone Family Office first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 1 quarter.
  • Pathstone Family Office's Arcturus Therapeutics position peaked at $11K in Q4 2020.
  • 162 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.